

## ASSIGNMENT

WHEREAS, APPLIED MOLECULAR EVOLUTION, INC., ASSIGNOR, a Delaware Corporation, having an office and principal place of business at 3520 Dunhill Road, San Diego, California 92121, by virtue of an assignment from William D. Huse, Jeffry D. Watkins, and Herren Wu, possesses a right, title, and interest in and to the following:

Application for United States Letters Patent Serial No. 10/900,230, filed July 26, 2004, in the names of James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffry D. Watkins and Herren Wu for **METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT** and the invention described therein,

Application for United States Letters Patent Serial No. 10/962,285, filed October 8, 2004, in the names of James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffry D. Watkins and Herren Wu for **METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT** and the invention described therein,

United States Letters Patent No. 6,818,216, issued November 16, 2004, in the names of James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffry D. Watkins and Herren Wu for **ANTI-RSV ANTIBODIES** and the invention described therein, and

United States Letters Patent No. 6,855,493, issued February 15, 2005, in the names of James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffry D. Watkins and Herren Wu for **METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT** and the invention described therein; and

WHEREAS, MEDIMMUNE, INC. a Delaware Corporation, having a place of business at 35 West Watkins Mill Road, Gaithersburg, Maryland 20878, ASSIGNEE, is desirous of obtaining the entire right, title and interest in, to and under the invention claimed in the said United States Letters Patents and applications for United States Letters Patents; and


WHEREAS, in accordance with the terms of the Research and Assignment and License Agreement of February 24, 1999 by and between Ixsys, Inc. (now Applied Molecular Evolution, Inc.) and MedImmune, Inc., the said ASSIGNOR, has sold, assigned, transferred and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, its entire right, title and interest in, to and under (a) the said invention, and (b) the said United States applications and patents and all divisions, renewals and continuations thereof, and all Patents of the United States and foreign countries which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States and foreign applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof (collectively "PATENT RIGHTS");

NOW, THEREFORE, ASSIGNOR HEREBY confirms such sale, assignment, transfer, and setting over unto ASSIGNEE, its successors, legal representatives and assigns, its entire right, title and interest in, to and under (a) the said invention, and (b) the said PATENT RIGHTS;

AND ASSIGNOR HEREBY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

IN WITNESS WHEREOF, this 8<sup>th</sup> day of September, 2005, APPLIED MOLECULAR EVOLUTION, INC. has caused this assignment to be executed by its duly authorized officer as specified below:

APPLIED MOLECULAR EVOLUTION, INC.

BY: 

Vice President, Biotechnology Discovery  
Research/Applied Molecular Evolution, Inc.

TITLE: \_\_\_\_\_

WITNESSED BY: 

WITNESSED BY: 